As­traZeneca’s res­pi­ra­to­ry group scores FDA OK for a block­buster se­vere asth­ma drug

This was the year that an­a­lysts had fixed on As­traZeneca’s first hur­dle in a com­bi­na­tion study for lung can­cer as the big cat­a­lyst of the year, which would show whether or not CEO Pas­cal So­ri­ot was on track to fi­nal­ly turn the phar­ma gi­ant around af­ter five long years at the helm.

As­traZeneca missed that goal, caus­ing con­sid­er­able fret­ting about its fu­ture. But it didn’t end there. Events have con­spired to pro­vide As­traZeneca with a se­ries of H2 wins, capped to­day with an FDA ap­proval for its asth­ma drug ben­ral­izum­ab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.